OBJECTIVE: To assess the levels of expression of the antiapoptotic gene Bcl-2 and the proapoptotic gene Bax in circulating mononuclear cells (CMNC) harvested during the course of severe sepsis (SS) in formerly non-immunocompromised patients undergoing hospital-acquired infection, in parallel to cytokine levels. DESIGN: Prospective study. SETTING: Intensive care unit. PARTICIPANTS: A total of 24 patients without immunodeficiency undergoing standard goal-directed therapy for nosocomial SS, 10 critically ill patients without sepsis, and 10 healthy controls. INTERVENTIONS: Blood was collected before infection and within 12 h, 1, 3 and 7 days after fever onset, to determine plasma concentrations of IL-6, IL-10, TNF-alpha, C-reactive protein, whole blood cell counts, lymphocyte subsets, annexin V labelling for apoptosis, and Bax and Bcl-2 relative RNA expression by real-time polymerase chain reaction. RESULTS: SS patients displayed increased cytokine concentrations, TNF-alpha being significantly increased at full-blown sepsis. Within 12 h after onset of infection, lymphocyte counts were lower in SS patients than in critically ill controls ( p=0.001), and this phenomenon was marked in CD4+ and CD8+ subsets ( p<0.001). This was associated with enhanced apoptosis in CMNC (15.7+/-8.7% vs 3.4+/-2.1%, p<0.001) and a significant down-expression of the Bcl-2 gene throughout the study ( p<0.05). In contrast, the expression of Bax did not change significantly. Within 12 h of fever onset, non-survivors expressed a 10-fold down-expression of Bcl-2 when compared to survivors ( p<0.001). CONCLUSIONS: An early transient down-expression of the gene Bcl-2 occurred in CMNC harvested from SS patients who died despite intensive care. In contrast, the expression of the gene Bax did not change significantly.
OBJECTIVE: To assess the levels of expression of the antiapoptotic gene Bcl-2 and the proapoptotic gene Bax in circulating mononuclear cells (CMNC) harvested during the course of severe sepsis (SS) in formerly non-immunocompromised patients undergoing hospital-acquired infection, in parallel to cytokine levels. DESIGN: Prospective study. SETTING: Intensive care unit. PARTICIPANTS: A total of 24 patients without immunodeficiency undergoing standard goal-directed therapy for nosocomial SS, 10 critically ill patients without sepsis, and 10 healthy controls. INTERVENTIONS: Blood was collected before infection and within 12 h, 1, 3 and 7 days after fever onset, to determine plasma concentrations of IL-6, IL-10, TNF-alpha, C-reactive protein, whole blood cell counts, lymphocyte subsets, annexin V labelling for apoptosis, and Bax and Bcl-2 relative RNA expression by real-time polymerase chain reaction. RESULTS: SS patients displayed increased cytokine concentrations, TNF-alpha being significantly increased at full-blown sepsis. Within 12 h after onset of infection, lymphocyte counts were lower in SS patients than in critically ill controls ( p=0.001), and this phenomenon was marked in CD4+ and CD8+ subsets ( p<0.001). This was associated with enhanced apoptosis in CMNC (15.7+/-8.7% vs 3.4+/-2.1%, p<0.001) and a significant down-expression of the Bcl-2 gene throughout the study ( p<0.05). In contrast, the expression of Bax did not change significantly. Within 12 h of fever onset, non-survivors expressed a 10-fold down-expression of Bcl-2 when compared to survivors ( p<0.001). CONCLUSIONS: An early transient down-expression of the gene Bcl-2 occurred in CMNC harvested from SS patients who died despite intensive care. In contrast, the expression of the gene Bax did not change significantly.
Authors: R S Hotchkiss; K W Tinsley; P E Swanson; R E Schmieg; J J Hui; K C Chang; D F Osborne; B D Freeman; J P Cobb; T G Buchman; I E Karl Journal: J Immunol Date: 2001-06-01 Impact factor: 5.422
Authors: T Menges; J Engel; I Welters; R M Wagner; S Little; R Ruwoldt; M Wollbrueck; G Hempelmann Journal: Crit Care Med Date: 1999-04 Impact factor: 7.598
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker; Benoit Vallet Journal: Intensive Care Med Date: 2005-02-18 Impact factor: 17.440
Authors: Maria Angeles Ballesteros; Marcos López-Hoyos; Pedro Muñoz; Maria Jose Marin; Eduardo Miñambres Journal: Intensive Care Med Date: 2006-09-09 Impact factor: 17.440
Authors: Eduardo Miñambres; Herminio Lopez-Escribano; María A Ballesteros; Marta Peña; Marcos López-Hoyos Journal: Intensive Care Med Date: 2005-04-21 Impact factor: 17.440
Authors: Kevin R Kasten; Priya S Prakash; Jacqueline Unsinger; Holly S Goetzman; Lisa G England; Cindy M Cave; Aaron P Seitz; Cristina N Mazuski; Tony T Zhou; Michel Morre; Richard S Hotchkiss; David A Hildeman; Charles C Caldwell Journal: Infect Immun Date: 2010-09-07 Impact factor: 3.441
Authors: Mary White; Vivienne Mahon; Robert Grealy; Derek G Doherty; Patrick Stordeur; Dermot P Kelleher; Ross McManus; Thomas Ryan Journal: Crit Care Date: 2011-06-28 Impact factor: 9.097
Authors: Peter Weber; Ping Wang; Stephane Maddens; Paul Sh Wang; Rongqian Wu; Michael Miksa; Weifeng Dong; Michael Mortimore; Julian M C Golec; Peter Charlton Journal: Crit Care Date: 2009-09-09 Impact factor: 9.097
Authors: Stefan U Weber; Jens-Christian Schewe; Lutz E Lehmann; Stefan Müller; Malte Book; Sven Klaschik; Andreas Hoeft; Frank Stüber Journal: Crit Care Date: 2008-10-16 Impact factor: 9.097